Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors
摘要:
A series of novel thiapyran-pyrimidine derivatives (10a-10h, 11a-11g, 12a-12f, 13a-13f, 14a-14f) were synthesized and their antiproliferative activities were tested. Most of the target compounds showed good activity on one or more cancer cell lines but low activity on human normal cell LO2. The most promising compound 13a exhibited the similar IC50 values on A549 and H1975 cell lines to the lead drug Olmutinib, and exhibited excellent activity and selectivity on EGFR(T790M/L858R) in the kinase experiment. AO and Hoechst33258 staining indicated that 13a could effectively induce H1975 cells apoptosis. Cell cycle and apoptosis analysis suggested that 13a could block cancer cells in G2/M phase and induce into late apoptosis in a manner of concentration-dependent. The structure-activity relationship of 13a was analyzed to explore its mechanism. All the results showed that 13a was a promising EGFR inhibitor.
Three new routes to derivatives of alpha-fluoracrylic acid, including a laboratory synthesis and a large-scale method, are reported. The processes are (i) addition of elementary fluorine to acrylic esters and subsequent elimination of HF; (ii) addition of difluorocarbene to isopropenyl methyl ether, oxidation via ring opening and dehalogenation; and (iii) 'nitrofluorination' of 2,3-dichloropropene, hydrolysis and dechlorination.
Two series of olmutinib derivatives containing an acrylamide moiety were designed and synthesized, and their IC50 values against cancer cell lines (A549, H1975, NCI-H460, LO2, and MCF-7) were evaluated. Most of the compounds exhibited moderate cytotoxic activity against the five cancer cell lines. The most promising compound, H10, showed not only excellent activity against EGFR kinase but also positive
Five series of novel thiophene-pyrimidine derivatives (9a-h, 10a-f, 11a-f, 12a-f, 13a-f) have been synthesized and tested for their anti-proliferative activity against several cancer cell lines in which EGF is highly expressed. Most of the target compounds showed excellent activity against one or more cancer cell lines. The most promising compound 13a, of which IC50 values on of cell lines A549 and
A direct and simple catalytic coupling of nonfluorinated and fluorinated silylbutenamides with β-CF3 α,β-unsaturated esters mediated by fluorideion was carried out. The transformation proceeded with excellent yields to afford new, highly functionalized trifluoromethylated and quaternary fluorinated products.